115 related articles for article (PubMed ID: 16148645)
21. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
Levi-Schaffer F; Nagler A; Slavin S; Knopov V; Pines M
J Invest Dermatol; 1996 Jan; 106(1):84-8. PubMed ID: 8592087
[TBL] [Abstract][Full Text] [Related]
23. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
24. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
[TBL] [Abstract][Full Text] [Related]
26. Orthotopic Wilms tumor xenografts derived from cell lines reflect limited aspects of tumor morphology and clinical characteristics.
Mengelbier LH; Bexell D; Sehic D; Ciornei CD; Gisselsson D
Pediatr Blood Cancer; 2014 Nov; 61(11):1949-54. PubMed ID: 25044705
[TBL] [Abstract][Full Text] [Related]
27. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Soffer SZ; Moore JT; Kim E; Huang J; Yokoi A; Manley C; O'Toole K; Stolar C; Middlesworth W; Yamashiro DJ; Kandel JJ
J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
[TBL] [Abstract][Full Text] [Related]
28. Halofuginone: a novel antifibrotic therapy.
Pines M; Nagler A
Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of rat renal fibroblast proliferation by halofuginone.
Haran N; Leschinski L; Pines M; Rapoport J
Nephron Exp Nephrol; 2006; 104(1):e35-40. PubMed ID: 16735800
[TBL] [Abstract][Full Text] [Related]
32. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma.
Ghanem MA; Van Der Kwast TH; Den Hollander JC; Sudaryo MK; Mathoera RB; Van den Heuvel MM; Noordzij MA; Nijman RJ; van Steenbrugge GJ
Cancer; 2001 Dec; 92(12):3120-9. PubMed ID: 11753991
[TBL] [Abstract][Full Text] [Related]
33. Halofuginone inhibits collagen deposition in fibrous capsules around implants.
Olbrich KC; Meade R; Bruno W; Heller L; Klitzman B; Levin LS
Ann Plast Surg; 2005 Mar; 54(3):293-6;discussion 296. PubMed ID: 15725837
[TBL] [Abstract][Full Text] [Related]
34. Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation.
Cheng H; Tian J; Zeng L; Pan B; Li Z; Song G; Chen W; Xu K
Hematology; 2012 Sep; 17(5):261-7. PubMed ID: 22971531
[TBL] [Abstract][Full Text] [Related]
35. Reduction in pulmonary fibrosis in vivo by halofuginone.
Nagler A; Firman N; Feferman R; Cotev S; Pines M; Shoshan S
Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1082-6. PubMed ID: 8887611
[TBL] [Abstract][Full Text] [Related]
36. Silencing of hypoxia inducible factor-1α by RNA interference inhibits growth of SK-NEP-1 Wilms tumour cells in vitro, and suppresses tumourigenesis and angiogenesis in vivo.
Shi B; Li Y; Wang X; Yang Y; Li D; Liu X; Yang X
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):626-33. PubMed ID: 27015631
[TBL] [Abstract][Full Text] [Related]
37. Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study.
Abramovitch R; Itzik A; Harel H; Nagler A; Vlodavsky I; Siegal T
Neoplasia; 2004; 6(5):480-9. PubMed ID: 15548356
[TBL] [Abstract][Full Text] [Related]
38. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
39. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
Leiba M; Cahalon L; Shimoni A; Lider O; Zanin-Zhorov A; Hecht I; Sela U; Vlodavsky I; Nagler A
J Leukoc Biol; 2006 Aug; 80(2):399-406. PubMed ID: 16769768
[TBL] [Abstract][Full Text] [Related]
40. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.
Spira G; Mawasi N; Paizi M; Anbinder N; Genina O; Alexiev R; Pines M
J Hepatol; 2002 Sep; 37(3):331-9. PubMed ID: 12175628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
